ZA878183B - Ifosphamide lyophilisate and process for its preparation - Google Patents

Ifosphamide lyophilisate and process for its preparation

Info

Publication number
ZA878183B
ZA878183B ZA878183A ZA878183A ZA878183B ZA 878183 B ZA878183 B ZA 878183B ZA 878183 A ZA878183 A ZA 878183A ZA 878183 A ZA878183 A ZA 878183A ZA 878183 B ZA878183 B ZA 878183B
Authority
ZA
South Africa
Prior art keywords
ifosphamide
lyophilisate
preparation
ifosfamide
weight
Prior art date
Application number
ZA878183A
Other languages
English (en)
Inventor
Sauerbier Dieter
Dammann Uwe-Peter
Isaac Otto
Original Assignee
Asta Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Pharma Aktiengesellschaft filed Critical Asta Pharma Aktiengesellschaft
Publication of ZA878183B publication Critical patent/ZA878183B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Control Of El Displays (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Amplifiers (AREA)
  • Indole Compounds (AREA)
ZA878183A 1986-10-31 1987-10-30 Ifosphamide lyophilisate and process for its preparation ZA878183B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3637089 1986-10-31

Publications (1)

Publication Number Publication Date
ZA878183B true ZA878183B (en) 1988-05-02

Family

ID=6312873

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA878183A ZA878183B (en) 1986-10-31 1987-10-30 Ifosphamide lyophilisate and process for its preparation

Country Status (25)

Country Link
EP (1) EP0265812B1 (esLanguage)
JP (1) JPS63159319A (esLanguage)
KR (1) KR900003491B1 (esLanguage)
AT (1) ATE55250T1 (esLanguage)
AU (1) AU598602B2 (esLanguage)
CA (1) CA1314231C (esLanguage)
DD (1) DD262582A5 (esLanguage)
DE (1) DE3764235D1 (esLanguage)
DK (1) DK169308B1 (esLanguage)
EG (1) EG18333A (esLanguage)
ES (1) ES2017982B3 (esLanguage)
FI (1) FI87140C (esLanguage)
GE (1) GEP19971025B (esLanguage)
GR (1) GR3000708T3 (esLanguage)
HU (1) HU197987B (esLanguage)
IL (1) IL84312A (esLanguage)
IN (1) IN168119B (esLanguage)
LV (1) LV10051B (esLanguage)
MX (1) MX8958A (esLanguage)
NO (1) NO873860L (esLanguage)
PT (1) PT86032B (esLanguage)
RU (1) RU1836079C (esLanguage)
UA (1) UA11075A (esLanguage)
YU (1) YU197387A (esLanguage)
ZA (1) ZA878183B (esLanguage)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2040394T3 (es) * 1988-03-19 1993-10-16 Asta Medica Aktiengesellschaft Procedimiento para preparar un material liofilizado de ifosfamida y mesna.
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
WO1995007083A1 (en) * 1993-09-10 1995-03-16 F.H. Faulding & Co. Limited Ifosfamide lyophilisate composition
DE19529057B4 (de) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
AU757002B2 (en) * 1998-03-03 2003-01-30 Eli Lilly And Company Pharmaceutical compositions containing the phospholipase inhibitor sodium ((3-(2-amino-1,2-dioxoethyl)-2-ethyl-1- phenylmethyl)-1H-indol-4-YL)oxy)acetate
EA008776B1 (ru) * 2002-09-05 2007-08-31 Бхарат Сирумс Энд Вэксинс Лтд. Жидкая стабильная композиция оксазафосфорина с месной
DE60332385D1 (de) * 2002-12-02 2010-06-10 Bharat Serums & Vaccines Ltd Ifosfamid-zusammensetzungen zur parenteralen verabreichung und verfahren für ihre herstellung
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
EP2071917B1 (en) * 2006-09-29 2012-11-21 Infa S.A. Packaging system for pharmaceutical compositions and kit for intravenous administration
CN105900385B (zh) * 2014-12-04 2019-08-27 华为技术有限公司 在数据通信网中的负载分配

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3732340A (en) * 1966-07-11 1973-05-08 Asta Werke Ag Chem Fab N',o-propylene phosphoric acid ester diamides
DE2750207A1 (de) * 1977-05-09 1978-11-16 Walton J Smith Gefriergetrocknete zusammensetzungen, insbesondere gefriergetrocknete pharmazeutische praeparate und verfahren zu deren herstellung
DE3279834D1 (en) * 1981-12-31 1989-08-31 Asta Pharma Ag 4-sulfido-oxaza phosphorines and their use in the treatment of cancer, and in immunosuppression
US4537883A (en) * 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide

Also Published As

Publication number Publication date
IL84312A (en) 1991-11-21
AU598602B2 (en) 1990-06-28
RU1836079C (ru) 1993-08-23
DE3764235D1 (de) 1990-09-13
LV10051A (lv) 1994-05-10
FI87140C (fi) 1992-12-10
DD262582A5 (de) 1988-12-07
GR3000708T3 (en) 1991-10-10
NO873860L (no) 1988-05-02
MX8958A (es) 1993-12-01
IL84312A0 (en) 1988-03-31
HUT44932A (en) 1988-05-30
FI87140B (fi) 1992-08-31
GEP19971025B (en) 1997-04-06
ES2017982B3 (es) 1991-03-16
PT86032A (de) 1987-11-01
ATE55250T1 (de) 1990-08-15
EG18333A (en) 1993-12-30
FI874727L (fi) 1988-05-01
PT86032B (pt) 1990-08-31
YU197387A (en) 1988-12-31
JPH0543684B2 (esLanguage) 1993-07-02
DK569687A (da) 1988-05-01
EP0265812B1 (de) 1990-08-08
UA11075A (uk) 1996-12-25
HU197987B (en) 1989-07-28
DK169308B1 (da) 1994-10-10
LV10051B (en) 1995-06-20
KR880004814A (ko) 1988-06-27
CA1314231C (en) 1993-03-09
IN168119B (esLanguage) 1991-02-09
KR900003491B1 (ko) 1990-05-21
AU8052987A (en) 1988-05-05
DK569687D0 (da) 1987-10-30
JPS63159319A (ja) 1988-07-02
FI874727A0 (fi) 1987-10-27
NO873860D0 (no) 1987-09-15
EP0265812A1 (de) 1988-05-04

Similar Documents

Publication Publication Date Title
EP0427247A3 (en) Pharmaceutical composition with r-alpha-lipoic acid or s-alpha-lipoic acid as the active ingredient
GR3007251T3 (esLanguage)
EP0348808A3 (de) Neue Arzneimittelformulierung sowie Verfahren zu deren Herstellung
LU90949I2 (fr) Esters aminoalcohol d'acide thienylcarboxyliques leurs produits quaternaires leur préparation et l'utilisation de ces composés
GR3002377T3 (en) Ifosfamide-mesna-lyophilized composition and process to prepare it
DE3766200D1 (de) L-dopa enthaltendes arzneimittel.
EP0259139A3 (en) Novel pyridinylpyrimidine derivatives, method for production thereof and a plant disease protectant containing them as the active ingredient
EP0303697A4 (en) Derivatives of physiologically active substance k-252.
EG18333A (en) Process for preparing ifosphamide lyophilisate
AU7492187A (en) Improved stabilizers for live vaccines, process for their preparation and vaccines containing them
DK23490A (da) Implanteret antibiotisk tilberedning med reguleret frigivelse
ZA894667B (en) Process for the preparation of 2,6-dichlorodiphenyl-amino-acetic derivatives
IL82145A0 (en) Substituted thiacycloalkeno(3,2-b)pyridines,their preparation and pharmaceutical compositions containing them
HUT39150A (en) Process for preparing immunologically active compounds
GR3003638T3 (esLanguage)
GR3001481T3 (en) Preparation of trichlorophenol
CA2022323A1 (en) Excretion of potassium ion by prostanoic acid derivatives
IL83495A0 (en) Oxirane pseudooligosaccharides,a process for their preparation,and pharmaceutical preparations containing them
EP0415564A3 (en) Improvement of excretion of nonprotein nitrogen into the intestine by prostanoic acid derivaties
AU1732888A (en) Stable 5-fluorouracil compositions
IT1186793B (it) Frazione ottenuta da listeria monocytogenes avente attivita' terapeutica,procedimento per la sua preparazione e composioni farmaceutiche che la contengono